These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21070598)

  • 1. Targeting AML through DR4 with a novel variant of rhTRAIL.
    Szegezdi E; Reis CR; van der Sloot AM; Natoni A; O'Reilly A; Reeve J; Cool RH; O'Dwyer M; Knapper S; Serrano L; Quax WJ; Samali A
    J Cell Mol Med; 2011 Oct; 15(10):2216-31. PubMed ID: 21070598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.
    Reis CR; van der Sloot AM; Natoni A; Szegezdi E; Setroikromo R; Meijer M; Sjollema K; Stricher F; Cool RH; Samali A; Serrano L; Quax WJ
    Cell Death Dis; 2010 Oct; 1(10):e83. PubMed ID: 21368856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
    Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B
    Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
    Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
    Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
    Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
    Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
    Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
    J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-Inflammatory Activation Suppresses TRAIL-induced Apoptosis of Acute Myeloid Leukemia Cells.
    Kobyakova MI; Senotov AS; Krasnov KS; Lomovskaya YV; Odinokova IV; Kolotova AA; Ermakov AM; Zvyagina AI; Fadeeva IS; Fetisova EI; Akatov VS; Fadeev RS
    Biochemistry (Mosc); 2024 Mar; 89(3):431-440. PubMed ID: 38648763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
    Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
    Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.
    Ouyang W; Yang C; Liu Y; Xiong J; Zhang J; Zhong Y; Zhang G; Zhou F; Zhou Y; Xie C
    Int J Oncol; 2011 Dec; 39(6):1577-86. PubMed ID: 21769428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
    Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
    Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.